Intravenous Cocaine Discrimination in Humans

人类静脉注射可卡因歧视

基本信息

  • 批准号:
    6612678
  • 负责人:
  • 金额:
    $ 34.65万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2002
  • 资助国家:
    美国
  • 起止时间:
    2002-07-15 至 2005-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Cocaine abuse/dependence remains a major social and public health problem. There are a significant number of cocaine dependent individuals for whom current behavioral treatment interventions are ineffective. Finding a successful pharmacological treatment for cocaine abuse/dependence continues to be an important yet elusive goal. Several compounds have been shown in pre-clinical studies to attenuate the discriminative stimulus and reinforcing effects of intravenous cocaine but when these medications have been tested in clinical trials, none have proven effective. It is not clear whether the lack of concordance is a function of the behavioral procedures that are used in these models or to a species difference. One strategy to answer this question is to conduct similar studies in humans to assess the validity of the animal models. Although there are established methods for studying the subjective, physiological, and reinforcing effects of intravenous cocaine in humans, drug discrimination methods with intravenous cocaine have not been developed. The potential advantage of studying the discriminative stimulus effects of drugs is that this procedure is particularly well suited for studying mechanisms underlying the dependence-related effects of drugs and has the potential to be relatively efficient, allowing several candidate medications to be evaluated over a relatively short period of time. The goal of this application is to establish the validity of an intravenous cocaine discrimination paradigm in humans. In the first study, human participants will be trained to discriminate the effects of intravenous cocaine injections. Dose-response functions will then be generated with cocaine doses higher and lower than the training dose and generalization tests will be conducted with doses of a drug similar pharmacologically to cocaine (d-amphetamine) and a drug different from cocaine (pentobarbital) to determine the specificity of the paradigm. The second study will determine whether oral cocaine can attenuate the subjective, physiological, and discriminative stimulus effects of intravenous cocaine injections. Although oral cocaine would be an unlikely medication for cocaine dependence, studies of the reinforcing effects of cocaine have demonstrated that they are blocked following the administration of oral cocaine and that this approach functions as a proof of concept in the absence of established blocking agents. These studies as a whole will investigate a promising new strategy for developing treatment medications for cocaine abuse/dependence. If successful, this will be an efficient paradigm for examining the ability of compounds to attenuate the effects of cocaine in humans and may lead to a successful pharmacological treatment for cocaine abuse/dependence.
描述(由申请人提供):可卡因滥用/依赖仍然是一个主要的社会和公共卫生问题。有相当数量的可卡因依赖者,目前的行为治疗干预措施对他们无效。寻找一种成功的可卡因滥用/依赖药物治疗仍然是一个重要但难以实现的目标。在临床前研究中,有几种化合物被证明可以减弱静脉注射可卡因的辨别刺激和强化作用,但当这些药物在临床试验中进行测试时,没有一种被证明是有效的。目前尚不清楚缺乏一致性是否是这些模型中使用的行为程序的功能,还是物种差异。回答这个问题的一个策略是在人类中进行类似的研究,以评估动物模型的有效性。虽然已经建立了研究静脉注射可卡因在人体中的主观、生理和强化作用的方法,但尚未开发出静脉注射可卡因的药物鉴别方法。研究药物的区别性刺激效应的潜在优势在于,这种方法特别适合于研究药物依赖性相关效应的机制,并且具有相对有效的潜力,可以在相对较短的时间内对几种候选药物进行评估。本申请的目的是建立静脉注射可卡因的歧视范例在人类中的有效性。在第一项研究中,人类参与者将接受培训,以区分静脉注射可卡因的影响。然后将用高于和低于训练剂量的可卡因剂量生成剂量-反应函数,并将用与可卡因类似的药物(d-安非他明)和与可卡因不同的药物(戊巴比妥)的剂量进行泛化测试,以确定范例的特异性。第二项研究将确定口服可卡因是否能减弱静脉注射可卡因的主观、生理和辨别刺激效应。虽然口服可卡因不太可能是治疗可卡因依赖的药物,但对可卡因强化作用的研究表明,口服可卡因后,可卡因的强化作用被阻断,在没有既定阻断剂的情况下,这种方法可作为概念验证。这些研究作为一个整体,将调查一个有前途的新战略,开发治疗药物的可卡因滥用/依赖。如果成功的话,这将是一个有效的范例,用于检查化合物的能力,以减轻可卡因在人类的影响,并可能导致一个成功的药物治疗可卡因滥用/依赖。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHRIS-ELLYN JOHANSON其他文献

CHRIS-ELLYN JOHANSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHRIS-ELLYN JOHANSON', 18)}}的其他基金

Kappa Opioid Antagonist for Cocaine Addiction
用于治疗可卡因成瘾的 Kappa 阿片类药物拮抗剂
  • 批准号:
    7085671
  • 财政年份:
    2005
  • 资助金额:
    $ 34.65万
  • 项目类别:
Intravenous Cocaine Discrimination in Humans
人类静脉注射可卡因歧视
  • 批准号:
    6542226
  • 财政年份:
    2002
  • 资助金额:
    $ 34.65万
  • 项目类别:
Intravenous Cocaine Discrimination in Humans
人类静脉注射可卡因歧视
  • 批准号:
    6751687
  • 财政年份:
    2002
  • 资助金额:
    $ 34.65万
  • 项目类别:
Brain Imaging of Tobacco Craving Using fMRI
使用功能磁共振成像对烟草渴望进行脑成像
  • 批准号:
    6317176
  • 财政年份:
    2001
  • 资助金额:
    $ 34.65万
  • 项目类别:
Brain Imaging of Tobacco Craving Using fMRI
使用功能磁共振成像对烟草渴望进行脑成像
  • 批准号:
    6515852
  • 财政年份:
    2001
  • 资助金额:
    $ 34.65万
  • 项目类别:
Brain Imaging of Tobacco Craving Using fMRI
使用功能磁共振成像对烟草渴望进行脑成像
  • 批准号:
    6634343
  • 财政年份:
    2001
  • 资助金额:
    $ 34.65万
  • 项目类别:
Brain Imaging of Tobacco Craving Using fMRI
使用功能磁共振成像对烟草渴望进行脑成像
  • 批准号:
    6664829
  • 财政年份:
    2001
  • 资助金额:
    $ 34.65万
  • 项目类别:
PHARMACOLOGICAL STUDIES OF BUPRENORPHINE
丁丙诺啡的药理学研究
  • 批准号:
    6332485
  • 财政年份:
    2000
  • 资助金额:
    $ 34.65万
  • 项目类别:
PHARMACOLOGICAL STUDIES OF BUPRENORPHINE
丁丙诺啡的药理学研究
  • 批准号:
    6300708
  • 财政年份:
    2000
  • 资助金额:
    $ 34.65万
  • 项目类别:
PHARMACOLOGICAL STUDIES OF BUPRENORPHINE
丁丙诺啡的药理学研究
  • 批准号:
    6201565
  • 财政年份:
    1999
  • 资助金额:
    $ 34.65万
  • 项目类别:

相似海外基金

Digital cognitive-behavior therapy for anxiety and depressive disorders: Building an impactful research project from international partnerships and knowledge exchange in primary care
针对焦虑和抑郁症的数字认知行为疗法:通过初级保健领域的国际合作和知识交流建立一个有影响力的研究项目
  • 批准号:
    480808
  • 财政年份:
    2023
  • 资助金额:
    $ 34.65万
  • 项目类别:
    Miscellaneous Programs
Function of cost bias and effect of cognitive behavior therapy on social anxiety in children and adolescents
成本偏差的作用及认知行为治疗对儿童青少年社交焦虑的影响
  • 批准号:
    23K02970
  • 财政年份:
    2023
  • 资助金额:
    $ 34.65万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Combined Dialectical Behavior Therapy and Digital Cognitive Behavioral Therapy for Insomnia for Adolescents at High Risk for Suicide: A Pilot RCT
辩证行为疗法和数字认知行为疗法相结合治疗自杀高危青少年的失眠:一项试点随机对照试验
  • 批准号:
    10643478
  • 财政年份:
    2023
  • 资助金额:
    $ 34.65万
  • 项目类别:
A Randomized Clinical Trial Comparing Transdiagnostic Behavior Therapy to Disorder-Specific Psychotherapy in the Recovery of Veterans with Social Anxiety Disorder and Comorbid PTSD Symptomatology
一项随机临床试验,比较跨诊断行为疗法与特定障碍心理疗法在患有社交焦虑症和共病 PTSD 症状的退伍军人康复中的作用
  • 批准号:
    10746930
  • 财政年份:
    2023
  • 资助金额:
    $ 34.65万
  • 项目类别:
Reducing suicide risk among aging caregivers of persons with AD/ADRD: Adapting, implementing, and evaluating Dialectical Behavior Therapy skills training interventions.
降低 AD/ADRD 患者老年护理人员的自杀风险:调整、实施和评估辩证行为治疗技能培训干预措施。
  • 批准号:
    10730708
  • 财政年份:
    2023
  • 资助金额:
    $ 34.65万
  • 项目类别:
A Randomized control trial of behavior therapy of tics in Japan. Exploring the behavior model of tics.
日本抽动行为治疗的随机对照试验。
  • 批准号:
    22K13840
  • 财政年份:
    2022
  • 资助金额:
    $ 34.65万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The Role of Behavior Therapy Combined with Buprenorphine for the Treatment of Opioid Use Disorder
行为疗法联合丁丙诺啡治疗阿片类药物使用障碍的作用
  • 批准号:
    10440820
  • 财政年份:
    2022
  • 资助金额:
    $ 34.65万
  • 项目类别:
Efficacy of digital cognitive behavior therapy for insomnia for the prevention of perinatal depression
数字认知行为疗法治疗失眠预防围产期抑郁症的疗效
  • 批准号:
    10429841
  • 财政年份:
    2022
  • 资助金额:
    $ 34.65万
  • 项目类别:
Efficacy of digital cognitive behavior therapy for insomnia for the prevention of perinatal depression
数字认知行为疗法治疗失眠预防围产期抑郁症的疗效
  • 批准号:
    10656415
  • 财政年份:
    2022
  • 资助金额:
    $ 34.65万
  • 项目类别:
Efficacy of digital cognitive behavior therapy for insomnia for the prevention of perinatal depression - supplement
数字认知行为疗法治疗失眠预防围产期抑郁症的疗效 - 补充
  • 批准号:
    10794868
  • 财政年份:
    2022
  • 资助金额:
    $ 34.65万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了